Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels

Pituitary

Volumn 7, Issue 3, 2004, Pages 139-144

  Lindsay, J R ^a   McConnell, E M ^a   Hunter, S J ^a   McCance, D R ^a   Sheridan, B ^a   Atkinson, A B ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Growth hormone; Octreotide; Remission

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; HUMAN GROWTH HORMONE;

ACROMEGALY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS; LIFE EXPECTANCY; LONG TERM CARE; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT FAILURE; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ACROMEGALY; ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; TIME FACTORS;

EID: 33644670829     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-1756-2     Document Type: Article

References (25)

1. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223(4):327-335.
2. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730-2734.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-152.
4. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol Metab 1998;83(10):3411-3418.
5. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86(5):293-299.
6. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87(9):4054-4058.
7. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999;50(5):561-567.
8. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85(12):4596-4602.
9. Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85(7):2476-2482.
10. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1(2):105-114.
11. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87(9):4142-4146.
12. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87(10):4554-4563.
13. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990;71(2):391-397.
14. van der Lely AJ dHW, Lamberts SW. New medical treatment for acromegaly. Pituitary 1999;2(1):89-92.
15. Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JG. Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf) 1988;29(4):411-420.
16. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246-254.
17. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81(6):2356-2362.
18. McKnight JA, McCance DR, Sheridan B, McIlrath E, Hadden DR, Kennedy L, et al. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly. Clin Endocrinol (Oxf) 1991;34(2):119-125.
19. Campbell MJ M. Medical Statistics (3rd edition). Wiley & Sons, Chichester 1999.
20. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(7):3013-3018.
21. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003;58(4):387-399.
22. Pieters GFFM SA, Kloppenborg PWC. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1986;314(21):1391.
23. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995;80(9):2768-2775.
24. Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999;22(6):409-418.
25. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results? J Clin Endocrinol Metab 2003;88(7):3090-3098.